Prenatal Correction of X-Linked Hypohidrotic Ectodermal Dysplasia

Area of Science:

• Developmental biology
• Genetics
• Regenerative medicine

Background:

• X-linked hypohidrotic ectodermal dysplasia (XLHED) results from genetic deficiency of ectodysplasin A (EDA).
• EDA is crucial for the development of ectodermal structures, including sweat glands, leading to irreversible impairment in XLHED patients.
• Impaired sweat gland function can cause life-threatening hyperthermia.

Observation:

• Normal development of mouse fetuses with Eda mutations was observed after in utero exposure to a recombinant EDA protein.
• This protein includes the receptor-binding domain of EDA.

Findings:

• Intra-amniotic administration of recombinant EDA protein to human fetuses affected with XLHED at gestational weeks 26 and 31 (twins) and week 26 (singleton) resulted in normal sweating ability post-birth.
• Infants treated prenatally showed no development of XLHED-related illness up to 14-22 months of age.

Implications:

• Prenatal protein therapy offers a potential treatment for XLHED, addressing the root cause of the genetic disorder.
• This approach may prevent severe complications associated with XLHED, such as hyperthermia.
• The findings open avenues for therapeutic interventions targeting developmental genetic disorders during gestation.